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Abstract
Increased prevalence of DM is accompanied by increased in its various complications include diabetic nephropathy, 
which can lead to end stage renal disease (ESRD). Urinary albumin-creatinine ratio (uACR) is the gold standard 
for diabetic nephropathy; however, it has several limitations, including the inability to early diagnose due to the 
absence of increased level in uACR. Uromodulin is produced by thick ascending limb (TAL) at Henle’s loop and 
early distal tubule of nephron. Uromodulin will decrease when tubular atrophy occurs in early stage of renal 
impairment with normoalbuminuria. The aim of this study was to determine the validity of serum uromodulin in 
type 2 diabetes mellitus (T2DM) in identifying diabetic nephropathy by comparing it with uACR as gold standard. 
This study was a cross-sectional analytical observational study at Dr. Hasan Sadikin (RSHS) Bandung from June to 
August 2020. Subjects consisted of 62 patiens with T2DM. Results showed that the serum uromodulin level had 
a sensitivity of 93.3%, a specificity of 88.2%, a positive predictive value of 95.5%, a negative predictive value of 
83.3%, and an accuracy of 91,9% and an AUC value of 0.975. The cut-off point of serum uromodulin in this study 
was 47.195 ng/mL. In conclusion, serum uromodulin, when compared to the uACR as the gold standard, has good 
sensitivity and specificity for identifying diabetic nephropathy.
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Validitas Uromodulin Serum Sebagai Penanda Diagnosis Dini Nefropati 
Diabetes Pada Diabetes Melitus Tipe 2
Abstrak
Peningkatan prevalensi DM diiringi dengan peningkatan komplikasi yang ditimbulkan, salah satunya adalah 
nefropati diabetes yang dapat berakhir menjadi end stage renal disease (ESRD). Pemeriksaan urinary albumin-
creatinine ratio (uACR) memiliki keterbatasan mendiagnosis gangguan fungsi ginjal tahap awal, disebabkan belum 
terjadinya peningkatan kadar albumin urine, serta sebagian besar gangguan ginjal pada pasien DM terjadi pada 
keadaan normoalbuminuria. Uromodulin diproduksi oleh sel-sel epitel yang melapisi thick ascending limb (TAL) 
di loop of Henle dan tubulus distal, kadar uromodulin menurun saat atrofi tubulus pada tahap awal gangguan 
fungsi ginjal. Tujuan penelitian ini adalah menganalisis validitas uromodulin serum sebagai penanda diagnosis 
dini nefropati diabetes pada T2DM dengan baku emas uACR. Penelitian ini analitik observasional deskriptif 
khusus dengan rancangan penelitian potong lintang yang dilakukan di RSUP Dr. Hasan Sadikin Bandung pada 
bulan Juni–Agustus 2020. Subjek penelitian adalah 62 penderita T2DM dari Poliklinik Endokrin RSUP Dr. Hasan 
Sadikin Bandung. Hasil uji validitas pada penelitian ini menunjukkan sensitivitas 93,3%, spesifisitas 88,2%, 
nilai duga positif 95,5%, nilai duga negatif 83,3%, akurasi 91,9% serta nilai area under the curve (AUC) 0,975. 
cut-off point uromodulin serum penelitian ini sebesar 47,195 ng/mL. Kesimpulan dari penelitian ini, validitas 
pemeriksaan kadar uromodulin serum terhadap baku emas uACR memiliki sensitivitas dan spesifisitas yang baik.
Kata kunci: Albuminuria, diabetes melitus tipe 2 (T2DM), nefropati diabetes, urinary albumin-creatinine ratio 
        (uACR), uromodulin serum
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Introduction
Chronic kidney disease (CKD) is disease with 
reduced kidney function with the most common 
risk and the most prevalent comorbidity found 
is diabetes mellitus (DM). Diabetes mellitus itself 
is a condition caused by metabolic disorders due 
to pancreas being unable to produce hormone 
insulin adequately or when the body unable to 
use insulin effectively, resulting in increased 
blood glucose level.1 According to Centers of 
Disease Control Prevention (CDC) in 2019, DM is 
responsible for 38% of end stage renal disease 
(ESRD) incidence. In addition, about 20% of type 
1 diabetes mellitus (T1DM) or type 2 diabetes 
mellitus (T2DM) will develop into diabetic 
nephropathy in years. Diabetic nephropathy is 
a microvascular complication and being main 
cause of end stage renal disease (ESRD). Long 
term diabetes may cause impaired nephron 
function due to structural changes, such as 
focal tubular atrophy, thickening of basement 
membrane in glomerulus and tubular, expansion 
of mesangial cells accompanied by increased 
matrix (glomerulosclerosis).2 
In daily clinical practice, albuminuria is 
considered as a sign of the early development 
of diabetic nephropathy.3 As time goes by, few 
studies have shown that diabetic patients may 
still experience decreased kidney function due to 
diabetic nephropathy without changes in urine 
albumin levels or normoalbuminuria. 30–50% 
type 2 Diabetes Mellitus (T2DM) patients may 
regress to normoalbuminuria although they 
experience impaired kidney function.4
Biological markers currently used widely 
in daily clinical practice to evaluate diabetic 
nephropathy and decreased renal function 
include serum creatinine, urea, proteinuria, and 
albuminuria.5 However, laboratory tests such as 
serum creatinine and measurement of glomerular 
filtration rate (GFR) may only depict changes in 
kidney function over a long period of time or if 
50% of nephrons have damage.6,7 Meanwhile, 
detecting albuminuria can be undertook using 
urinary albumin-creatinine ratio (uACR) from 
random urine sample (urine spot).8 According 
to American Diabetes Association (ADA) 
and Perkumpulan Endokrinologi Indonesia 
(PERKENI) in 2015, uACR is the gold standard 
for diagnosing diabetic kidney disease. This 
examination has better predictive value than 
other parameters.9
To date, few studies have focused on 
strategies to develop biological markers that 
may overcome limitations of albuminuria and 
clinically useful for early detection of diabetic 
nephropathy or those who develop CKD.3 
One of them is uromodulin or Tamm-Horsfall 
protein, which is synthesized exclusively by 
thick ascending limb (TAL) epithelial cells of the 
loop of Henle and the distal tubule. The protein 
reaches renal interstitium and presents in serum 
at very low level (70–540 ng/mL). Compared 
to other biological markers of tubular damage, 
uromodulin being an independent, sensitive and 
predictive biological marker for renal tubular 
function, and can detect the risk of developing 
diabetic nephropathy early.10 In addition, 
previous studies have shown that serum 
uromodulin level are positively correlated with 
eGFR and negatively correlated with urinary 
albumin level.11 
The validity test denote ability of an 
examination to distinguish people with and 
without disease. Validity test include sensitivity, 
specificity, accuracy, positive predictive value 
and negative predictive value.11 The aim of this 
study to examine the validity of uromodulin 
examination, so that in the future it is expected 
to become an early diagnostic tool for diabetic 
nephropathy.
Methods
This study was an observational analytic study 
with cross-sectional study design which was 
conducted in June-August 2020. The subjects of 
this study were male and female patients who 
had been diagnosed with type 2 diabetes mellitus 
(T2DM) according to PERKENI criteria by 
clinicians at the Endocrine Polyclinic, RSUP. DR. 
Hasan Sadikin Bandung with eGFR 60–≥90 mL/
min/1,73 m2. The exclusion criteria are patient 
with urinary tract infection, athlete, smoker; 
patient who are taking losartan, fenofibrate and 
ruboxistaurin; hemolysis, lipemic and icteric 
blood sample; and insufficient urine sample.
A total 2 mL Blood was collected by 
phlebotomy on cubital vein, while urine used 
was + 10 mL mid-stream urine from random 
urine. Examination of serum uromodulin level 
was carried out using Sandwich ELISA method. 
Serum creatinine level was measured using 
kinetic Jaffe method. The material was stable 
serum at 2–8°C for 7 days, stable at -20°C less 
than 1 month, and stable at -80°C less than 3 
months. After obtaining serum creatinine result, 
eGFR was calculated. Examination of uACR level 
used Meditape II 10K strip test with a semi-
quantitative method. Material was examined at 
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the Central Laboratory of the Clinical Laboratory 
Installation of DR. Hasan Sadikin, Bandung. 
Sampling was done by consecutive sampling. 
Sensitivity value set at 50% (0.5%). Sample size 
formula for this diagnostic test was:
n= Zα/2 sens-(1-sens) 
Note:
n = Number of subjects
Zα/2 = Z value from normal distribution Table 
    for 95% confidence interval
    (Z = 1.96)
Sen  = Uromodulin sensitivity value to eGFR   
    (80%=0.80)
d = Study precision (20%)
P = Study prevalence (40%)12
Number of samples required based on sample 
formula to uACR was:
n = (1.96)2 * 0.5 * 0.5
            (0.2)2 * 0.40
n = 3.8416 x 0.25
           0.04 x 0.4
 n =  60
Anticipating data loss, number of samples 
was added to 10% of sample size, then minimum 
sample size was 60+6= 66.
Normality test for sample of more than 50 
people used Kolmogorov Smirnov test and 
Shapiro Wilk’s test for sample less than 50 people. 
Normality test was declared to be normally 
distributed if p>0.05. For normally distributed 
data using parametric analysis by unpaired t test 
and for data that were not normally distributed 
using non-parametric data analysis by Mann 
Whitney’s test and Chi square. Data analysis 
was performed using SPSS for windows version 
26.0 program at 95% confidence interval and 
statistically significant if p<0.05. The uromodulin 
data obtained will be analyzed with ROC curve to 
obtain a cut-off value for the diagnosis of diabetic 
nephropathy and calculate the area under the 
curve (AUC), then analyzed the validity value to 
uACR gold standard.24 This study was approved 
by the Health Research Ethics Committee of 
Dr. Hasan Sadikin General Hospital Bandung 




A total of 71 people with T2DM according to 
the PERKENI criteria by clinicians at Endocrine 
Polyclinic DR. Hasan Sadikin Bandung was 
included in this study. A total of 9 people were 
excluded from the study due to insufficient 
urine sample for uACR examination. Number of 
subjects in this study was 62 people who met 
the inclusion and exclusion criteria and were 
willing took part in the study by signing consent 
form after being given an explanation (informed 
consent).
Characteristics of subjects based on sex, age, 
BMI category, duration of diabetes, and eGFR 
calculation result are shown in Table 1. In this 
Table, study subjects are classified according to 
normoalbuminuria (uACR level <30 mg/gCr) 
and albuminuria (uACR level >30 mg/gCr).
From Table 1 above, 10 subjects from 
albuminuria group were male (58.8%), and 28 
subjects were women (62.2%). Mean age of the 
participants was + 63 years, and BMI categories 
ranging from normal to overweight. Majority 
of participants had had diabetes for less than 
5 years. Mean serum uromodulin level in 
normoalbuminuria group was two times higher 
than in albuminuria group.
Table 2 shows sensitivity and specificity 
value  of serum uromodulin level of various cut-
off value. Cut-off value  used in this study was 
47.195 with sensitivity and specificity, 93.3% 
and 88.2%, respectively.
Figure 1 shows the ROC curve of serum 
uromodulin level. From cut-off value of 47.2, area 
Uromodulin level
Figure 1 ROC Curve of Serum Uromodulin Level
R Dumpatna et al.: Validity of Serum Uromodulin as Early Diagnosis Marker of Diabetic Nephropathy in T2DM
Majalah Kedokteran Bandung, Volume 53 No. 2, June 2021110
R Dumpatna et al.: Validity of Serum Uromodulin as Early Diagnosis Marker of Diabetic Nephropathy in T2DM















































































a: Chi-Square test; b: unpaired T test; c: Mann Whitney test; *means p <0.05; significant or statistically significant
Table 2 Sensitivity and Specificity Value  of Serum Uromodulin Level From Various Cut 
  off Values
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under the curve (AUC) was found to be 97.5%. 
Referring to categories of diagnostic value, 
then it was included in very strong diagnostic 
classification.
In Table 3, sensitivity and specificity value 
obtained  were 93.3% and 88.2%, respectively. The 
sensitivity value indicated that 93.3% possibility 
of serum uromodulin level yielded low result 
in T2DM subjects with albuminuria. While the 
specificity value indicated that 88.2% possibility 
of serum uromodulin level will yielded high 
result in T2DM subjects with normoalbuminuria. 
Positive predictive value was 95.5%; 95.5% 
possibility of T2DM patients would experienced 
diabetic nephropathy (albuminuria) if the serum 
uromodulin level resulted more than 47.2 ng/
mL. Negative predictive value was 83.3%; 83.3% 
possibility of a person would not experienced 
diabetic nephropathy (normoalbuminuria) if the 
serum uromodulin level was more than 47.2 ng/
mL. The accuracy value was 91.9%.
Discussion
This current study found that most of subjects 
had had T2DM less than 5 years. This was 
consistent with study conducted by Alfehaid 
et al. which stated that there was statistically 
significant correlation regarding duration of 
T2DM with albuminuria. In addition, T2DM was 
associated with developing complications of 
diabetic nephropathy, thus ADA recommended 
performing uACR on all T2DM patients when 
diagnosed for the first time.13
Present study showed that  there was 
significant difference in median uromodulin 
level in T2DM albuminuria group (33.45 ng/
mL) and normoalbuminuria group (75.51 ng/
mL). Uromodulin is produced exclusively in the 
kidney by the epithelial cells of thick ascending 
limb (TAL) of Henle’s loop and distal tubule. Low 
serum uromodulin levels are associated with 
structural disorders of TAL.10 Related to T2DM, 
metabolic changes occur, such as hyperglycemia, 
which will cause tubular cells being hyperplasia, 
hypertrophy and then will stimulate interstitial 
inflammation resulting in interstitial fibrosis 
and tubular atrophy.6,7 Tubular damage occurs 
earlier than  glomerulus as diabetic nephropathy 
develops. Reduced serum uromodulin level 
occurs in early stage of diabetic nephropathy.4 
Previous study has also stated that decline in 
uromodulin level was found to be significant in 
the T2DM group with albuminuria. This could 
be due to the level of glycemic control associated 
with changes in renal tubular function that occur 
in the early stages of DM.14 
The uromodulin level has inverse correlation 
to CKD stage; higher CKD stage, lower 
uromodulin level.15 In Table 4, cut-off value of the 
serum uromodulin level was 47.2 ng/mL with 
sensitivity of 93.3% and a specificity of 88.2%; 
AUC 0.975. Several previous studies with eGFR 
gold standard, cut-off values  obtained were 
higher (125 ng/mL; 142.3 ng/mL; 163 ng/mL) 
compared to this study.16 Whereas previous study 
focused on correlation between uromodulin and 
uACR showed that higher uACR level, lower the 
uromodulin level would be.11 Uromodulin is not 
affected by age, sex, diet, muscle mass as well 
as infectious and inflammatory process; so the 
reason for differences in serum uromodulin level 
could be due to study population and total study 
sample used. Lower cut-off value  will lead to 
increased sensitivity and decreased specificity. 
Cut-off value established in this study was 47.2 
ng/mL with sensitivity of 93.3% and specificity 
of 88.2% (AUC 0.975) which indicated that 
serum uromodulin could be used as a screening 
test for early marker of diabetic nephropathy.
Table 4 shows that there were 2 of 17 (11.76%) 
subjects with normoalbuminuria yielded result 
of serum uromodulin level less than 47.2ng/
mL. Decreased eGFR indicated that measured 
kidney function decreased before albuminuria 
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Table 3 Validity of Serum Uromodulin Level Examination with uACR Gold Standard
T2DM
Total
(n=62)    Albuminuria                      Normoalbuminur
  (n=45)                                    (n=17)
Uromodulin (ng/mL)   ≤47,195 42                                              2 44
                                            >47,195   3                                              15 18
Note: Sensitivity = a / (a  + c) = 42/45 x 100% = 93.3%; Specificity = d / (b + d) = 15/17 x 100% = 88.2%; Positive 
Predictive Value = a / (a  + b) = 42/44 x 100% = 95.5%; Negative Predictive Value = d / (c + d) = 15/18 x 100% = 83.3%; 
Accuracy = (a + d) / N = 57/62 x 100% = 91.9%
Majalah Kedokteran Bandung, Volume 53 No. 2, June 2021112
develops.17 Whereas in normal eGFR, decreased 
uromodulin level may be a biological marker that 
can uniquely identify the condition of diabetic 
nephropathy.16 Decreased kidney function can 
develop temporarily when urine albumin level 
regress, so that decline in serum uromodulin 
level will be found without albuminuria.17 
There is 3 of 45 subjects with albuminuria 
with serum uromodulin level more than 47.2 ng/
mL. Previous studies has reported on early stage 
diabetic nephropathy have occurred reduction in 
total nephron mass, but an increase in the amount 
of uromodulin secreted by each functioning 
nephron (compensatory).15 Other studies have 
shown that serum uromodulin had negative 
correlation with eGFR, which was associated 
with measuring uromodulin level in blood not 
always reflect the amount of uromodulin in renal 
interstitium due to uromodulin binding with 
many immune cells.18 
There are several limitations in this study, 
namely the subjects did not know type of drug 
used certainly, activity factor and subject’s blood 
pressure were not measured when took the 
material, and the number of subjects were not 
balanced between the normoalbuminuria and 
albuminuria groups. Whereas blood pressure 
affects urine albumin level, urine albumin level 
were only checked once; not in accordance with 
the diagnostic criteria of diabetic nephropathy; 
at least two examinations in a period of 3-6 
months.
To conclude, validity of serum uromodulin 
level to uACR gold standard has good sensitivity 
and specificity. The cut-off value for serum 
uromodulin level for diabetic nephropathy 
screening was 47.2 ng/mL. Examination of serum 
uromodulin level can be used as an alternative 
of uACR test as a screening test of early marker 
of diabetic nephropathy. Examination of serum 
uromodulin level can yield another diagnostic 
value thereby reducing uncertainty in diagnosing 
diabetic nephropathy.
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